Wockhardt’s UK Business Grows But Other Markets Underperform

Company Sees Major Growth Come From COVID-19 Vaccine Business

Wockhardt has seen a good financial fourth quarter and full year for its UK business, which contributed 41% of the company’s global revenue in Q4 FY21 and 37% to its global revenue for the financial year thanks to its COVID-19 vaccine business. However, the company’s US, India, Ireland and emerging markets businesses delivered a weak fourth quarter.

UK GBP
Wockhardt’s UK business sees a 14% growth in quarterly sales and 13% growth in annual sales • Source: Alamy

Wockhardt Limited has enjoyed significant growth in its UK business, reporting an increase of 14% in sales to INR2.61bn ($35.7m) for the firm’s financial fourth quarter ended 31 March 2021. The company also saw an annual growth of 13% in UK sales, clocking in INR10.13bn for FY21.

The pharmaceutical and biotech company, which has been one of the largest suppliers into the UK’s National Health Service for...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business